Q3 2025 Earnings Estimate for Avantor, Inc. Issued By Zacks Research (NYSE:AVTR)

Avantor, Inc. (NYSE:AVTR) – Research analysts at Zacks Research cut their Q3 2025 earnings estimates for shares of Avantor in a note issued to investors on Thursday, September 19th. Zacks Research analyst D. Dey now anticipates that the company will earn $0.29 per share for the quarter, down from their prior estimate of $0.30. The consensus estimate for Avantor’s current full-year earnings is $1.01 per share.

Avantor (NYSE:AVTR) last issued its quarterly earnings results on Friday, July 26th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.02. Avantor had a return on equity of 12.40% and a net margin of 5.28%. The firm had revenue of $1.70 billion during the quarter, compared to analyst estimates of $1.70 billion.

Several other equities analysts have also weighed in on the stock. TD Cowen raised their price objective on shares of Avantor from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, July 29th. Citigroup cut shares of Avantor from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $30.00 to $23.00 in a report on Wednesday, July 10th. Wells Fargo & Company assumed coverage on Avantor in a report on Tuesday, August 27th. They issued an “overweight” rating and a $30.00 price target on the stock. Stifel Nicolaus raised their price objective on Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 target price on shares of Avantor in a research report on Monday, July 29th. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $27.40.

Avantor Trading Down 0.1 %

Shares of AVTR stock opened at $26.56 on Monday. The stock has a 50-day simple moving average of $25.26 and a 200 day simple moving average of $24.36. The stock has a market capitalization of $18.04 billion, a P/E ratio of 68.10, a P/E/G ratio of 2.75 and a beta of 1.32. Avantor has a fifty-two week low of $16.63 and a fifty-two week high of $28.00. The company has a quick ratio of 1.05, a current ratio of 1.59 and a debt-to-equity ratio of 0.89.

Hedge Funds Weigh In On Avantor

Hedge funds have recently added to or reduced their stakes in the company. Jennison Associates LLC raised its holdings in Avantor by 113.0% during the first quarter. Jennison Associates LLC now owns 2,497,349 shares of the company’s stock valued at $63,857,000 after buying an additional 1,325,026 shares in the last quarter. Swedbank AB bought a new stake in Avantor during the first quarter worth approximately $2,707,000. Diversify Advisory Services LLC bought a new stake in Avantor during the first quarter worth approximately $908,000. CenterBook Partners LP acquired a new position in Avantor during the fourth quarter valued at approximately $4,562,000. Finally, APG Asset Management US Inc. acquired a new stake in shares of Avantor in the fourth quarter worth $2,971,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Insider Activity at Avantor

In other news, CAO Steven W. Eck sold 3,525 shares of the company’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $25.06, for a total value of $88,336.50. Following the transaction, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at $740,372.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.50% of the stock is currently owned by insiders.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.